Avicanna Beheer

Beheer criteriumcontroles 3/4

De CEO Avicanna is Aras Azadian, benoemd in Jan2016, heeft een ambtstermijn van 8.83 jaar. De totale jaarlijkse vergoeding van { bedraagt CA$ 336.01K, bestaande uit 26.3% salaris en 73.7% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 4.01% van de aandelen van het bedrijf, ter waarde $ 875.06K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.9 jaar en 3.4 jaar.

Belangrijke informatie

Aras Azadian

Algemeen directeur

CA$336.0k

Totale compensatie

Percentage CEO-salaris	26.3%
Dienstverband CEO	8.8yrs
Eigendom CEO	4.0%
Management gemiddelde ambtstermijn	1.9yrs
Gemiddelde ambtstermijn bestuur	3.4yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Aras Azadian's beloning veranderd ten opzichte van Avicanna's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-CA$7m
Jun 30 2024	n/a	n/a	-CA$7m
Mar 31 2024	n/a	n/a	-CA$7m
Dec 31 2023	CA$336k	CA$88k	-CA$9m
Sep 30 2023	n/a	n/a	-CA$12m
Jun 30 2023	n/a	n/a	-CA$14m
Mar 31 2023	n/a	n/a	-CA$16m
Dec 31 2022	CA$486k	CA$161k	-CA$15m
Sep 30 2022	n/a	n/a	-CA$16m
Jun 30 2022	n/a	n/a	-CA$16m
Mar 31 2022	n/a	n/a	-CA$15m
Dec 31 2021	CA$244k	CA$127k	-CA$17m
Sep 30 2021	n/a	n/a	-CA$24m
Jun 30 2021	n/a	n/a	-CA$29m
Mar 31 2021	n/a	n/a	-CA$34m
Dec 31 2020	CA$358k	CA$110k	-CA$33m
Sep 30 2020	n/a	n/a	-CA$25m
Jun 30 2020	n/a	n/a	-CA$24m
Mar 31 2020	n/a	n/a	-CA$21m
Dec 31 2019	CA$608k	CA$240k	-CA$22m
Sep 30 2019	n/a	n/a	-CA$18m
Jun 30 2019	n/a	n/a	-CA$14m
Mar 31 2019	n/a	n/a	-CA$11m
Dec 31 2018	CA$150k	CA$150k	-CA$7m
Sep 30 2018	n/a	n/a	-CA$5m
Dec 31 2017	CA$180k	CA$150k	-CA$3m

Compensatie versus markt: De totale vergoeding ($USD 238.87K ) Aras } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 646.00K ).

Compensatie versus inkomsten: De vergoeding van Aras is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Aras Azadian

8.8yrs

Tenure

CA$336,008

Compensatie

Mr. Aras Azadian, M. Mgmt, Msc Management, B.Econ, MBA, is a Co-Founder of Avicanna Inc. He serves as Chief Executive Officer and Director since November 25, 2016 of Avicanna Inc. and served as its Chairma...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Aras Azadian	Co-Founder	8.8yrs	CA$336.01k	4.01% $ 875.1k
Phillip Cardella	Chief Financial Officer	1.9yrs	CA$254.02k	0.63% $ 136.6k
Ivana Maric	Executive Vice President of Marketing	no data	CA$249.08k	geen gegevens
Stephen Kim	Chief Legal Officer & General Counsel of Avicanna USA Inc.	1.9yrs	CA$396.48k	geen gegevens
Karolina Urban	Executive Vice President of Scientific & Medical Affairs	1.4yrs	CA$255.87k	geen gegevens
Arash Moghani	Executive Vice President of Operations & Technology	no data	geen gegevens	geen gegevens
Ingrid Diaz	VP, Assistant General Counsel & Corporate Compliance Officer	1.4yrs	geen gegevens	geen gegevens
Enric Pujol	Vice President of People	no data	geen gegevens	geen gegevens
Carlos Enrique Muete	SVP of Clinical Development	no data	geen gegevens	geen gegevens

1.9yrs

Gemiddelde duur

Ervaren management: Het managementteam van AVCN.F wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.9 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Aras Azadian	Co-Founder	8yrs	CA$336.01k	4.01% $ 875.1k
Sheldon Inwentash	Member of Business Advisory Board	no data	geen gegevens	5.54% $ 1.2m
Paul Fornazzari	Independent Director	less than a year	CA$12.31k	0.91% $ 199.1k
Daniel Sauder	Member of Global Scientific Advisory Board	no data	geen gegevens	geen gegevens
Giancarlo Char	Director	6.1yrs	CA$88.30k	0.63% $ 137.8k
Aline Masuda	Member of Business Advisory Board	no data	geen gegevens	geen gegevens
Mauricio Torres-Pradilla	Member of Global Scientific Advisory Board	no data	geen gegevens	geen gegevens
Humberto Reynales	Member of International Scientific Advisory Board	no data	geen gegevens	geen gegevens
Max Jones	Member of Global Scientific Advisory Board	no data	geen gegevens	geen gegevens
John McVicar	Independent Director	3.4yrs	CA$118.75k	0.45% $ 97.4k
Eileen McCormack	Independent Director	2.8yrs	CA$110.18k	0.25% $ 54.4k
Al Harrington	Member of Business Advisory Board	no data	geen gegevens	geen gegevens

3.4yrs

Gemiddelde duur

60yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van AVCN.F wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.4 jaar).

Avicanna Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Avicanna Inc., Annual General Meeting, Jul 10, 2024

Avicanna Announces Appointment of Paul Fornazzari to Board of Directors

Avicanna Inc. Announces Retirement of Chandra Panchal, PhD from the Board of Directors

Avicanna LATAM S.A.S. Announces Step Down of Lucas Nosiglia as President, Effective January 31, 2023

Assad Kazeminy Retires as Director of Avicanna Inc

Avicanna Inc., Annual General Meeting, Aug 31, 2022

Recent updates

Avicanna Inc. announced that it has received CAD 0.80001 million in funding

Avicanna Inc. announced that it has received CAD 1.986208 million in funding

Avicanna Announces United States Patent and Trademark Office Issuance of Patent SEDDS Technology

Avicanna Inc., Annual General Meeting, Jul 10, 2024

Avicanna Inc. Announces Results of Study in Patients with Epidermolysis Bullosa

Avicanna Inc. announced that it has received CAD 2.125584 million in funding

Avicanna Inc. Announces Completion of Topical Gel Observational Real-World Evidence Study

Avicanna Inc Announces the Canadian Launch of 10% CBD (THC Free) Proprietary Formulation

Avicanna Inc. to Report Fiscal Year 2023 Results on Apr 01, 2024

Avicanna Inc. Obtains Its First Indication-Specific Drug Registration with Trunerox

Avicanna Inc. announced that it has received CAD 0.888128 million in funding

Avicanna Announces Appointment of Paul Fornazzari to Board of Directors

Avicanna Inc. to Report Q3, 2023 Results on Nov 14, 2023

Avicanna Inc. Provides Update on the Successful Launch of MyMedi.ca

Avicanna Inc. Announces Retirement of Chandra Panchal, PhD from the Board of Directors

Avicanna Inc. announced that it has received CAD 1.455 million in funding

Avicanna Inc. (TSX:AVCN) completed the acquisition of Medical Cannabis by Shoppers Drug Mart Inc from Shoppers Drug Mart Inc.

Avicanna Inc. (TSX:AVCN) entered into definitive Asset Purchase Agreement to acquire Medical Cannabis by Shoppers Drug Mart Inc from Shoppers Drug Mart Inc. for CAD 2.6 million.

Avicanna LATAM S.A.S. Announces Step Down of Lucas Nosiglia as President, Effective January 31, 2023

Avicanna Inc. announced that it has received CAD 1.769097 million in funding

Avicanna and Santé Cannabis Initiate Real-World Evidence Study on Musculoskeletal Pain and Inflammation with the Rho Phytotm Cbg Transdermal Gel Topical Product

Avicanna Inc. Commercializes ‘Influid’, a Proprietary Water-soluble technology in the Canadian Market

Avicanna Inc. announced that it has received CAD 0.626763 million in funding

Avicanna Files Complete Patent Specifications Relating to A Novel Cannabinoid Formulation for Reducing Incidence of Seizures and Sudden Unexpected Death in Epilepsy

Avicanna Introduces a New Medical Cannabis Education Online Portal, "Avicenna Academy" for Health Care Professionals

Assad Kazeminy Retires as Director of Avicanna Inc

Avicanna Inc. announced that it has received CAD 2.782302 million in funding

Avicanna Inc., Annual General Meeting, Aug 31, 2022

An unknown buyer acquired 63 percent stake in Sativa Nativa S.A.S. from Avicanna Inc. (TSX:AVCN) for CAD 0.81 million.

Avicanna Inc. Announces Chief Financial Officer Changes

Avicanna Inc. announced that it has received CAD 1.473826 million in funding from Ei.Ventures, Inc.

Avicanna Inc. announced that it has received CAD 2.523568 million in funding

Avicanna Inc. Provides Consolidated Revenue Guidance for the Fourth Quarter, Full Year 2021 and Full Year 2022

Avicanna Inc. announced that it expects to receive CAD 1.3008 million in funding

Avicanna Inc. Launches Its Clinically Backed CBD Derma-Cosmetics Brand, Pura H&W, in the United States in Partnership with Red White and Bloom

Avicanna and Harrington Wellness Launch Re+Play™ Branded Cbd Topicals Products in Canada

Avicanna Inc. Files Patent to Protect its Advanced Oral Cannabinoid Platform and its Applications for Neurological Diseases

Avicanna Files US Patent Application for a Novel Cannabinoid Formulation in Reducing Incidence of Seizures and Sudden Unexpected Death in Epilepsy

Avicanna Inc. announced that it has received CAD 2.118 million in funding

Avicanna Inc. announced that it expects to receive CAD 2 million in funding

Avicanna and Bio-Gate Complete First Phase of Development on Cannabidiol (CBD) and Microsilver BG™ Based Skin Care Products for Global Commercialization

Avicanna Inc. Expands The Canadian Rho Phyto Product Offerings with the Addition of THC-Free High CBD Oral and Sublingual Formulation Across Medical and Adult Use Channels

Avicanna Inc.’s Pura Earth to Be Launched in Adult-Use and Medical Channels Across Canada in Second Quarter of 2021

Avicanna Inc. announced that it has received CAD 5.6 million in funding

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd